Antagonizing Bcl-2's BH4 domain in cancer by Vervloessem, Tamara et al.
 
 
                                                                                         
 
 
 
 
 
Many cancer cells, including B-cell and lung cancers, 
display elevated expression of anti-apoptotic Bcl-2 
proteins as a survival strategy to cope with oncogenic 
stress [1]. In cancer cells, Bcl-2 is loaded with pro-
apoptotic BH3-only proteins, thereby not only 
preventing Bax/Bak activation but also rendering them 
“primed to death” at the mitochondria. The last decade, 
different compounds have been developed to antagonize 
this anti-apoptotic function of Bcl-2 at the mitochondria 
[1]. The most promising molecules are the BH3 
mimetics (like ABT-737 and ABT-263), which release 
Bim from the hydrophobic cleft of Bcl-2 (or Bcl-XL) 
formed by the BH3-BH1-BH2 domains resulting in 
Bax/Bak-mediated apoptosis in cancer but not in 
healthy cells (Fig. 1). The last generation BH3 mimetics 
(ABT-199) spares platelets by avoiding Bcl-XL 
inhibition [1].  
Nowadays, the BH4 domain of Bcl-2 has emerged as an 
important anti-apoptotic mechanism by preventing Bax 
activation [2] and by inhibiting IP3 receptors, a major 
class of intracellular Ca2+-release channels involved in 
cell death and survival [3]. Importantly, cancer cells 
appear to exploit this function of Bcl-2 to prevent pro-
apoptotic Ca2+ release from the endoplasmic reticulum 
and mitochondrial Ca2+ overload. Recently, a stabilized 
cell-permeable IP3R-derived peptide, BIRD-2 (Bcl-
2/IP3 receptor Disruptor-2) was developed by 
Distelhorst and co-workers (Fig. 1). This peptide 
provoked, by antagonizing the BH4 domain of Bcl-2, 
pro-apoptotic Ca2+ signaling in a variety of lymphoid 
malignancies: primary chronic lymphocytic leukemia 
(CLL) and diffuse large B-cell lymphoma (DLBCL) 
cells (reviewed in [3]) and in multiple myeloma and 
follicular lymphoma cells [4]. BIRD-2-induced cell 
death, which involves Bax and caspase 3 activation, 
also resulted in a marked decrease in tumor growth in in 
vivo xenograft mouse [4]. Importantly, BIRD-2 did not 
cause a general cytotoxicity as peripheral mononuclear 
blood cells, certain DLBCL cells and non-malignant 
cell lines were very resistant to BIRD-2. Susceptibility 
of cancer cells to BIRD-2 was linked in DLBCL cell 
lines to the expression of the type 2 IP3 receptor, the 
isoform with the highest sensitivity towards its ligand 
IP3 (reviewed in [3]). Moreover, cancer cells that were 
more sensitive to BIRD-2 appeared more resistant to 
BH3  mimetics  and  vice  versa  [4].  This  is  important  
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since cancers poorly responding to conventional 
chemotherapy are also poor responders to BH3 
mimetics, as both responses depend on the 
“mitochondrial apoptotic priming” status [5]. 
Interestingly, Distelhorst and co-workers recently 
showed that prolonged exposure of myeloma cells to 
BIRD-2 elevated Bim-protein levels via a Ca2+-
dependent mechanism, thereby increasing their 
sensitivity to BH3-mimetics and inducing synergistic 
effects with these drugs [4]. Correlating with this, in 
BIRD-2-sensitive DLBCL cells, BIRD-2 could boost 
cell death provoked by HA14-1, a Bcl-2 inhibitor that 
also impacts Ca2+ signaling by inhibiting the 
sarco/endoplasmic reticulum Ca2+ ATPase [6]. 
Yet, the therapeutic applicability of native peptides in 
humans may be limited due to issues with (oral) bio-
availability and stability. Hence, Deng and co-workers 
identified, by screening chemical compounds, BDA-366 
that binds with very high affinity (Kd of ~3.3 nM) and 
selectivity to the BH4 domain of Bcl-2, but not to Bcl-
XL, Mcl-1 or Bfl-1 [7]. BDA-366 induced a 
conformational change in Bcl-2, resulting in the 
exposure of its BH3 domain that binds and activates 
Bax indirectly, leading to apoptosis (Fig. 1). Hence, 
BDA-366 resulted in cell death in different lung cancer 
cell lines with high levels of endogenous Bcl-2 but not 
in those with low or zero Bcl-2 levels. BDA-366, 
applied intraperitoneally, also prevented the growth of 
lung cancer cell lines and patients cells in in vivo 
xenograft mouse models without causing toxicity in 
healthy tissues. Moreover, current anti-lung cancer 
therapies inhibit mTOR, which adversely causes an 
upregulation of endogenous Bcl-2 levels. Importantly, 
BDA-366 displayed synergistic action with RAD001, 
an mTOR inhibitor currently used in the clinic for 
treating lung cancer. 
BDA-366 also disrupted Bcl-2 / IP3 receptor complexes 
and increased Fura-2 fluorescence, suggesting an effect 
on Ca2+ signaling. However, the impact of BDA-366 on 
Ca2+ dynamics and on interaction of Bcl-2 with IP3 
receptors as well as on the importance of Ca2+ signaling 
for BDA-366-induced cell death in normal and 
malignant cells require further study. Furthermore, it 
remains unknown whether other BH4-domain-targeting 
molecules can impact the conformation of Bcl-2. 
Moreover, by switching Bcl-2 into a pro-apoptotic 
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protein with an exposed BH3 domain, BDA-366 also 
results in the release of “activator” BH3-only proteins, 
like Bim, but their importance for BDA-366-induced 
apoptosis ought to be further characterized. Thus, 
facilitating the release of Bim using BH3 mimetics or 
boosting the expression of Bim using BIRD-2 might 
present interesting avenues to enhance BDA-366-
induced cell death. Further challenges towards its 
clinical applicability will also include (i) characterizing 
its effects in other Bcl-2-dependent cancers, (ii) 
examining its ability to boost other anti-cancer 
strategies currently used to treat these cancers (like 
chemotherapy, antibody therapy and phototherapy) and 
(iii) documenting its therapeutic window, thereby 
avoiding the potential adverse effects of such 
compounds on native, healthy tissues that express high 
endogenous levels of Bcl-2, including the hematopoietic 
system, endocrine glands like the thyroid gland, 
respiratory system like nasopharynx, reproductive 
systems, kidney and bladder 
(www.proteinatlas.org/ENSG00000171791-CL2/tissue). 
In conclusion, these recent studies [4, 7] reveal that 
antagonizing Bcl-2 via its BH4 domain holds potential 
for future cell-death therapies in different cancers, 
including those resistant to conventional chemotherapy/ 
BH3 mimetics. 
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Figure  1.    Two  functional  domains,  the  BH4  domain  and  the
hydrophobic  cleft,  are  important  for  Bcl‐2’s  anti‐apoptotic
function. The  transmembrane  (TM) domain anchors Bcl‐2  in ER
and  mitochondrial  membranes.  The  BH4  domain  suppresses
apoptosis by binding and inhibiting Bax (in mitochondria) and IP3
receptors  (in  ER).  The  hydrophobic  cleft  interacts with  several
pro‐apoptotic Bcl‐2 family members, including Bax/Bak and BH3‐
only proteins like Bim. BH3 mimetics, like ABT‐737, ABT‐263 and
ABT‐199, target the hydrophobic cleft of Bcl‐2 and release Bim,
leading  to  Bim‐mediated  activation  of  Bax/Bak  and  inducing
apoptosis. Furthermore, BIRD‐2  (Bcl‐2/IP3  receptor Disruptor‐2)
and  BDA‐366  have  been  developed  to  antagonize  Bcl‐2  via  its
BH4  domain  leading  to  apoptosis  although  via  different
mechanisms. BIRD‐2 provokes pro‐apoptotic Ca2+ signaling, while
BDA‐366 causes a conformational change in Bcl‐2, resulting in the
exposure of its BH3 domain, which will activate Bax. 
